U.S. Cell Banking Outsourcing Market Size, Share & Trends Analysis Report By Type (Master Cell Banking, Working Cell Banking, Viral cell Banking), By Cell Type (Stem Cell, Non-stem Cell), By Phase, And Segment Forecasts, 2024 - 2030

U.S. Cell Banking Outsourcing Market Trends

The U.S. cell banking outsourcing market size was estimated at USD 5.16 billion in 2023 and is expected to grow at a CAGR of 14.79% from 2024 to 2030. The driving factors for this growth include the rising cryopreservation & cell bank preparation methodologies, and escalating demand for monoclonal antibodies. Moreover, increasing R&D activities in this sector is likely to impact significantly over the forecast period.

The U.S. cell banking outsourcing market accounted for a 42% share of the global cell banking outsourcing market in 2023. The demand for cell banking is increasing due to the rise of cell therapies. Furthermore, the COVID-19 pandemic has had a significant impact on companies engaged in manufacturing MSC products from donated birth tissues, potentially leading to market growth post-pandemic. Additionally, funding and various initiatives are crucial in advancing stable cell lines and implementing new technologies for cell line storage and characterization, expediting market growth.

The market's growth has been driven by various factors, including the increasing production of vaccines, growing prevalence of cancer, rising number of cell banks, and escalating demand for monoclonal antibodies. These trends reflect a significant expansion in the industry, highlighting the importance of cell banking outsourcing services in supporting research and development activities across different sectors.

Moreover, outsourcing providers offer expertise and cutting-edge facilities, enabling access to state-of-the-art technologies that fulfill the demand for cell banking. Additionally, cell banking outsourcing aids in cost optimization by eliminating the necessity for internal infrastructure and resources, Thus, these factors drive growth and expansion of the cell banking outsourcing market.

Market Concentration & Characteristics

The U.S. cell banking outsourcing industry is fragmented with the presence of numerous small companies serving a wide array of services thereby maintaining a competitive edge. The market is growing at an accelerating pace due to startergies such as degree of innovation, mergers, and acquisitions, the impact of regulation, and expansion.

Companies in the U.S. cell banking outsourcing market are highly significantly influenced by a high degree of innovation to improve patient outcomes and sustain their position. Moreover, the provision of grants to perform innovative R and D activities further increases production efforts and demand in the industry. For instance, in September 2023, the Maryland Stem Cell Research Commission (MSCRC) announced a grant of approximately $4 million dedicated to fostering innovative research that will propel advancements in stem cell treatments and technologies across Maryland. This funding would boost the development of treatments for the liver, eyes, blood, bones, heart, nervous system, autoimmune system, and cancer.

Growing merger and acquisition (M&A) activities undertaken by key companies are expected to expand the industry growth. For instance, in October 2022 Pluristyx, panCELLa, and Implant Therapeutics management announced a merger agreement to provide end-to-end customer support and provide increased access to a wide range of induced pluripotent stem cell (iPSC)-related products and services. This initiative would offer streamlined access to the next generation of safe and cost-friendly iPSCs.

The approvals from regulatory bodies such U.S. FDA help in expanding clinical trial capabilities and company portfolio geographically, thereby escalating the industry growth. For instance, In August 2022, StemCyte announced US FDA approval for their Phase II clinical trial for the post-COVID syndrome (or PCS) using umbilical cord blood stem cell therapy.

Several market companies are involved in geographical expansion to enhance capabilities and have a direct presence in countries having high demand. For instance, in May 2023, US-based StemCures is set to establish a manufacturing lab in Telangana with a primary focus on stem cell therapy, aiming to develop the largest stem cell manufacturing plant in India.

Type Insights

Based on type, master cell banking dominated the market with a share of 64% in 2023 owing to its need for manufacturing and usage in working cell banks. Master cell banks are considered the primary source of cells that perform cell storage to maintain their viability. Moreover, the growing number of autoimmune diseases and cancer therapeutic approaches further boost the segment’s growth.

Working cell banking is projected to expand at the fastest CAGR from 2024 to 2030. Working cell banks serve as specialized repositories. They provide a continuous supply of renewable and consistent cells to perform research for biological drugs, therapies, and vaccines in biopharmaceutical companies. These applications increases the demand of this segment. This is anticipated to drive the market growth in the forecast period.

Cell Type Insights

Based on cell type, stem cell type held the largest share in 2023 and is expected to witness growth at the fastest CAGR over the forecast period owing to the widespread applicability of stem cells. Moreover, the grants offered by government authorities further elevate R&D activities in the stem cell sector thereby enhancing the demand for stem cells.

Non-cell stem type is anticipated to expand at a significant CAGR from 2024 to 2030. The non-stem includes somatic cells. These cells are further used in therapeutics for disease modeling, regenerative medicine, and drug discovery. These applications are anticipated to drive market growth over the forecast period.

Phase Insights

Based on phase, bank storage dominated the market with a share of 44% in 2023 due to the growing need for preservation techniques to support long-term storage of biological materials. Moreover, advanced cryopreservation methods are expected to fuel the segment’s growth over the forecast period.

Bank characterization& testing is projected to grow at the largest CAGR from 2024 to 2030. The outsourcing services of bank characterization & testing allow companies to access specialized services and capabilities, enhancing their ability to meet regulatory requirements and advance their research and development efforts in the field of cell therapy. For instance, Charles River Laboratories offers cell characterization and biosafety testing for MCBs, WCBs, and EoPCB or cells at the limit (CAL) of in vitro cell age used for production.

Key U.S. Cell Banking Outsourcing Company Insights

Key companies such as Cryo-Cell International, Inc., Charles River Laboratories, and Covance, along with others, are pivotal in driving advancements in the U.S. cell banking outsourcing sector. These leading companies prioritize continuous development and enhancement of their products to meet growing demand and expand their customer base. Additionally, strategic mergers and acquisitions, innovative product introductions, and initiatives for regional product expansion play a crucial role in propelling market growth.

Recent Developments

• In January 2024, STEMCELL Technologies announced the acquisition of Propagenix Inc., a US-based biotechnology company to present developing technologies to enable new approaches in regenerative medicine.

• In February 2024, Charles River Laboratories International, Inc. partnered with Pluristyx Inc., for cell therapy development. This collaboration grants Charles River extensive access to well-defined and distinctive stem cell lines, such as top-notch embryonic stem (ES) cells and induced pluripotent stem cells (iPSCs), to aid in the advancement of novel therapeutic solutions.

U.S. Cell Banking Outsourcing Market Report Scope

U.S. Cell Banking Outsourcing Market Report Segmentation

This report forecasts revenue growth at the country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2018 to 2030. For this study, Grand View Research has segmented the U.S. Cell Banking Outsourcing market based on type, cell type, and phase:

• Type Outlook (Revenue, USD Million, 2018 - 2030)

  • Master Cell Banking

  • Working Cell Banking

  • Viral Cell Banking

• Cell Type Outlook (Revenue, USD Million, 2018 - 2030)

  • Stem Cell

    • Cord Cell Banking

    • Embryonic Stem Cell Banking

    • Adult Stem Cell Banking

    • Dental Stem Cell Banking

    • IPS Stem Cell Banking

  • Non-stem Cell

• Phase Outlook (Revenue, USD Million, 2018 - 2030)

  • Bank Storage

    • Master Cell Bank Storage

    • Working Cell Bank Storage

    • Cell Storage Stability Testing

  • Bank Characterization & Testing

    • Safety Testing

      • Viral Cell Banks

      • Microbial Cell Banks

    • Gene Expression Testing

    • Karyology Testing

    • Gene Sequencing Testing

  • Bank Preparation

    • Master Cell Bank Preparation

    • Working Cell Bank Preparation